We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Microbial Identification Microarray Identifies 300 Oral Bacterial Species

By Labmedica staff writers
Posted on 29 Jan 2008
Molecular analyses based on 16S rRNA sequencing allow the simultaneous detection of about 300 of the most prevalent oral bacterial species, in a single hybridization. More...
The high throughput technology used allows the evaluation of species that cannot yet be grown in vitro.

The Forsyth Institute (Boston, MA, USA) microbial identification microarray service (MIM) enables rapid identification of bacterial species in clinical samples. The first offering, human oral microbe identification microarray (HOMIM), will focus on detection of bacterial profiles from the oral cavity. Scientists can use this service to compare bacterial associations in health vs. disease, monitor the effects of therapy on the oral ecology, and perform microbial perturbation studies.

Hundreds of different species of bacteria are able to live in the human mouth, although these are not usually present in the same mouth at the same time. Many of the oral bacteria have not been identified because they are impossible to grow in culture in the laboratory. Using molecular techniques, the Forsyth laboratories developed new tools, which do not depend on traditional culturing approaches, to hunt for oral microorganisms. Because the causative agents of oral diseases are not fully known, it is probable that many of the novel bacterial species identified by these new methods play important roles in disease.

The oral cavity also encompasses many surfaces, including teeth, the tongue, palate, and the oral mucosa, each coated with a plethora of bacteria. Using HOMIM, the Forsyth scientists have shown that different consortia of bacteria preferentially attach to different oral surfaces.

Philip Stashenko, president and CEO of The Forsyth Institute said, "The expertise of the Forsyth team is unparalleled and it can provide the scientific community with a unique opportunity to carry out global analyses of oral microbial ecology. In the future, we plan to introduce other microarrays which focus on bacteria in different body niches including the GI tract, stomach and skin.”


Related Links:
The Forsyth Institute

New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated PCR System
OnePCR
New
PSA Assay
CanAg PSA EIA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.